Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.66 |
| ▸ | FNTB | P49356 | 8/20 | 0.66 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18042466 | 0.98 | FNTA (0.69) | FNTAFNTBPGGT1BALDH1A1ALOX15 | |
| SCHEMBL5322450 | 0.93 | FNTA (0.59) | FNTAFNTBPGGT1BALDH1A1ALOX15 | |
| SCHEMBL5322445 | 0.93 | FNTA (0.59) | FNTAFNTBPGGT1BALDH1A1ALOX15 | |
| SCHEMBL109366 | 0.93 | FNTA (0.67) | FNTAFNTBPGGT1BALDH1A1ALOX15 | |
| SCHEMBL18042460 | 0.91 | FNTA (0.69) | FNTAFNTBPGGT1BALDH1A1ALOX15 | |
| SCHEMBL16655449 | 0.91 | FNTA (0.69) | FNTAFNTBPGGT1BALDH1A1ALOX15 | |
| SCHEMBL1978483 | 0.91 | FNTA (0.69) | FNTAFNTBPGGT1BALDH1A1ALOX15 | |
| SCHEMBL335749 | 0.88 | FNTA (0.75) | FNTAFNTBPGGT1B | |
| SCHEMBL335748 | 0.88 | FNTA (0.75) | FNTAFNTBPGGT1B | |
| SCHEMBL3099416 | 0.87 | FNTA (0.74) | FNTAFNTBPGGT1BALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621982-B | Biosynthesis method of geranyl diphosphate and application of geranyl diphosphate in preparation of cannabis compounds | 嘉兴欣贝莱生物科技有限公司 | 2023-11-07 | — | — | CN | claimed |
| CN-114621982-A | Biosynthesis method of geranyl diphosphate and application of geranyl diphosphate in preparation of cannabis compounds | 嘉兴欣贝莱生物科技有限公司 | 2022-06-14 | — | — | CN | claimed |
| US-20220127649-A1 | ENGINEERED CELLS FOR IMPROVED PRODUCTION OF CANNABINOIDS | CREO INGREDIENTS, INC. | 2022-04-28 | — | — | US | claimed |
| US-20200299735-A1 | METABOLIC ENGINEERING FOR MICROBIAL PRODUCTION OF TERPENOID PRODUCTS | SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2020-09-24 | — | — | US | claimed |
| US-20200080115-A1 | Cannabinoid Production by Synthetic In Vivo Means | Biotic Sciences LLC | 2020-03-12 | — | — | US | claimed |
| WO-2018144996-A1 | METABOLIC ENGINEERING FOR MICROBIAL PRODUCTION OF TERPENOID PRODUCTS | Manus Bio, Inc. (US) | 2018-08-09 | — | — | WO | claimed |
| EP-1088333-A4 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | claimed |
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | claimed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | claimed |
| EP-1088333-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | Merck & Co., Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | claimed |
| WO-1999067809-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-12460234-B2 | Synthesis of isoprenoids and derivatives | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4523674-B1 | COMPOSITION FOR PROMOTING PHOTOPROTECTION AND CUTANEOUS REGENERATION THROUGH SEQUENTIAL PHOTONIC TRANSFER (SPT) | ESPADA REGALADO JESUS (ES) | 2025-10-15 | — | — | EP | disclosed |
| US-20250288509-A1 | Composition for Promoting Photoprotection and Cutaneous Regeneration through Sequential Photonic Transfer (SPT) | REGALADO, JESUS ESPADA (ES) | 2025-09-18 | — | — | US | disclosed |
| US-20250207160-A1 | CELL-FREE PRODUCTION OF GERANYL PYROPHOSPHATE FROM GLYCEROL IN A CELL-FREE MANUFACTURING SYSTEM | Debut Biotechnology, Inc. | 2025-06-26 | — | — | US | disclosed |
| EP-0730603-A4 | DNA ENCODING LIMONENE SYNTHASE FROM -i(MENTHA SPICATA) | UNIV WASHINGTON (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5639653-A | ADMINISTERING MONOALKYL- OR ALKENYL-PYROPHOSPHATE TO MAMMAL TO STIMULATE LYMPHOCYTE CELL GROWTH AND ENHANCE IMMUNE RESPONSE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, A DIVISION OF YESHIVA UNIVERSTIY (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0730603-A1 | DNA ENCODING LIMONENE SYNTHASE FROM $i(MENTHA SPICATA) | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995011913-A1 | DNA ENCODING LIMONENE SYNTHASE FROM $i(MENTHA SPICATA) | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | SOST, PTEN, ALPI | FNTA 129/4885FNTB 751/4885PGGT1B 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.